{"id":"recombinant-factor-ix","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis (deep vein thrombosis, pulmonary embolism)"},{"rate":null,"effect":"Inhibitor development (anti-factor IX antibodies)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":{"setId":"f5070a92-96b8-476a-a2dc-18b22d95e5e0","title":"RIXUBIS (COAGULATION FACTOR IX (RECOMBINANT)) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Factor IX is a vitamin K-dependent serine protease essential for the intrinsic and common coagulation pathways. In hemophilia B (Christmas disease), factor IX is deficient or dysfunctional, leading to impaired thrombin generation and bleeding. Recombinant factor IX is produced via recombinant DNA technology and functions as a direct replacement therapy, restoring the ability to form stable blood clots.","oneSentence":"Recombinant factor IX replaces the missing or deficient clotting factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:36.423Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia B (factor IX deficiency) — prevention and treatment of bleeding episodes"},{"name":"Hemophilia B — perioperative management and surgical prophylaxis"}]},"trialDetails":[{"nctId":"NCT06883240","phase":"","title":"An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-04-29","conditions":"Von Willebrand Disease, Type 3","enrollment":40},{"nctId":"NCT04590950","phase":"","title":"Dosage and PD Study of Eftrenonacog-alfa","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":"Severe Haemophilia B","enrollment":15},{"nctId":"NCT04563520","phase":"PHASE3","title":"SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-03","conditions":"Hemophilia A","enrollment":5},{"nctId":"NCT04647227","phase":"PHASE4","title":"SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors","status":"RECRUITING","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2021-06-28","conditions":"Hemophilia A With Inhibitor, Hemophilia B With Inhibitor","enrollment":55},{"nctId":"NCT06399289","phase":"PHASE3","title":"Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"CSL Behring","startDate":"2024-07-28","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT07290634","phase":"","title":"Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion","status":"RECRUITING","sponsor":"Zeliha Alicikus","startDate":"2026-01-30","conditions":"Thromboembolus, Massive Blood Transfusion; Thrombocytopenia, Trauma","enrollment":4},{"nctId":"NCT04023019","phase":"","title":"Treatment of Hemophilia A Patients With FVIII Inhibitors","status":"RECRUITING","sponsor":"Emory University","startDate":"2020-03-17","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT04543383","phase":"PHASE1","title":"A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-07-27","conditions":"Healthy","enrollment":52},{"nctId":"NCT01154231","phase":"","title":"BeneFIX Drug Use Results Survey [All-Case Surveillance]","status":"COMPLETED","sponsor":"Pfizer","startDate":"2009-10-29","conditions":"Hemophilia B","enrollment":314},{"nctId":"NCT05695391","phase":"PHASE3","title":"A Phase 3 Study of the Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for the Prevention of Excessive Bleeding in Patients With Congenital Hemophilia A or B With Inhibitors to Factor VIII or IX Undergoing Elective Major Surgical Procedures SCOPE HIM","status":"TERMINATED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2024-06-07","conditions":"Hemophilia","enrollment":2},{"nctId":"NCT05203679","phase":"PHASE2, PHASE3","title":"Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Xinzhi BioMed Co., Ltd.","startDate":"2021-12-30","conditions":"Hemophilia B","enrollment":32},{"nctId":"NCT05281718","phase":"EARLY_PHASE1","title":"Factor IX as Adjunctive Therapy to Emicizumab (EMIX)","status":"COMPLETED","sponsor":"Tulane University","startDate":"2022-08-01","conditions":"Hemophilia A","enrollment":12},{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT01561391","phase":"PHASE4","title":"Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1998-04","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":36},{"nctId":"NCT06158334","phase":"","title":"Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®)","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"2022-06-01","conditions":"Hemophilia A, Hemophilia B","enrollment":400},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT02053792","phase":"PHASE3","title":"A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2014-02-06","conditions":"Hemophilia B","enrollment":97},{"nctId":"NCT04286412","phase":"PHASE4","title":"Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-02-10","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT02234310","phase":"PHASE3","title":"Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2014-11-13","conditions":"Hemophilia B","enrollment":33},{"nctId":"NCT02448680","phase":"PHASE3","title":"A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2015-12-07","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":25},{"nctId":"NCT02548143","phase":"PHASE3","title":"LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures","status":"COMPLETED","sponsor":"Laboratoire français de Fractionnement et de Biotechnologies","startDate":"2016-08-25","conditions":"Hemophilia","enrollment":12},{"nctId":"NCT02546622","phase":"","title":"ATHN 2: Factor Switching Study","status":"COMPLETED","sponsor":"American Thrombosis and Hemostasis Network","startDate":"2015-09","conditions":"Hemophilia","enrollment":310},{"nctId":"NCT03995784","phase":"PHASE2","title":"Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Catalyst Biosciences","startDate":"2019-06-18","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT01286779","phase":"PHASE3","title":"BAX 326 (rFIX) Continuation Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-04-12","conditions":"Hemophilia B","enrollment":117},{"nctId":"NCT01174446","phase":"PHASE3","title":"Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-07-29","conditions":"Hemophilia B","enrollment":86},{"nctId":"NCT01488994","phase":"PHASE2, PHASE3","title":"BAX 326 Pediatric Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-20","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT01507896","phase":"PHASE3","title":"BAX 326 Surgery Study in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-19","conditions":"Hemophilia B","enrollment":30},{"nctId":"NCT01757405","phase":"PHASE3","title":"Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-02-20","conditions":"Hemophilia A, Hemophilia B","enrollment":40},{"nctId":"NCT02922231","phase":"","title":"Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-01-06","conditions":"Hemophilia B","enrollment":57},{"nctId":"NCT02796222","phase":"","title":"Factor Product Utilization and Health Outcomes in Patients With Hemophilia","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2016-04","conditions":"Hemophilia A, Congenital, Hemophilia B, Congenital","enrollment":61},{"nctId":"NCT01128881","phase":"PHASE4","title":"IMMUNINE Pre-Treatment Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-05-31","conditions":"Hemophilia B","enrollment":57},{"nctId":"NCT00768287","phase":"PHASE2, PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2009-01","conditions":"Hemophilia B","enrollment":77},{"nctId":"NCT02190149","phase":"","title":"Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2014-07-22","conditions":"Hemophilia A, Hemophilia B","enrollment":64},{"nctId":"NCT01271868","phase":"PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B","status":"TERMINATED","sponsor":"Medexus Pharma, Inc.","startDate":"2010-11","conditions":"Hemophilia B","enrollment":9},{"nctId":"NCT01027364","phase":"PHASE3","title":"Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2009-12","conditions":"Severe Hemophilia B","enrollment":123},{"nctId":"NCT01440946","phase":"PHASE3","title":"Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2012-06","conditions":"Hemophilia B","enrollment":30},{"nctId":"NCT00716716","phase":"PHASE1","title":"Phase I/IIa Study of FIXFc in Hemophilia B Patients","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2008-04","conditions":"Hemophilia B","enrollment":10},{"nctId":"NCT01425723","phase":"PHASE3","title":"Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2011-12-08","conditions":"Severe Hemophilia B","enrollment":120},{"nctId":"NCT02392156","phase":"","title":"Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes","status":"TERMINATED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2015-07","conditions":"Hemophilia A, Hemophilia B","enrollment":3},{"nctId":"NCT04108260","phase":"PHASE4","title":"The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2020-04-21","conditions":"Hemophilia","enrollment":5},{"nctId":"NCT03272568","phase":"EARLY_PHASE1","title":"Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-02-14","conditions":"Hemophilia, Menstrual Flow Excessive","enrollment":3},{"nctId":"NCT02618915","phase":"PHASE1, PHASE2","title":"Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B","status":"TERMINATED","sponsor":"Ultragenyx Pharmaceutical Inc","startDate":"2015-12-16","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT03091751","phase":"PHASE2","title":"Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B","status":"COMPLETED","sponsor":"Grifols Biologicals, LLC","startDate":"2005-08","conditions":"Hemophilia B","enrollment":13},{"nctId":"NCT02020369","phase":"PHASE3","title":"Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors","status":"COMPLETED","sponsor":"rEVO Biologics","startDate":"2014-04","conditions":"Hemophilia A With Inhibitors, Hemophilia B With Inhibitors","enrollment":27},{"nctId":"NCT02336178","phase":"PHASE4","title":"Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-01","conditions":"HEMOPHILIA B","enrollment":70},{"nctId":"NCT00956345","phase":"PHASE1","title":"Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-08","conditions":"Congenital Bleeding Disorder, Haemophilia B","enrollment":18},{"nctId":"NCT00710619","phase":"","title":"Observational Patient Diary Study of Treatment Doses for Patients With Haemophilia With Inhibitors to Factors VIII and IX","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors","enrollment":52},{"nctId":"NCT02048111","phase":"PHASE3","title":"Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B","status":"WITHDRAWN","sponsor":"Cangene Corporation","startDate":"2014-03","conditions":"Hemophilia B","enrollment":""},{"nctId":"NCT02213250","phase":"PHASE1","title":"An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-03","conditions":"Hemophilia B","enrollment":12},{"nctId":"NCT01361126","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-07","conditions":"Hemophilia B","enrollment":17},{"nctId":"NCT01496274","phase":"PHASE2, PHASE3","title":"A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-02","conditions":"Hemophilia B","enrollment":63},{"nctId":"NCT01662531","phase":"PHASE3","title":"A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2013-01","conditions":"Hemophilia B","enrollment":27},{"nctId":"NCT01335061","phase":"PHASE3","title":"Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT01352143","phase":"","title":"Thrombin Generation in Neonatal Plasma After Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Emory University","startDate":"2011-03","conditions":"Cardiopulmonary Bypass","enrollment":24},{"nctId":"NCT00484185","phase":"","title":"Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-08","conditions":"Hemophilia B","enrollment":183},{"nctId":"NCT00244114","phase":"","title":"Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-02","conditions":"Hemophilia B","enrollment":20},{"nctId":"NCT01233440","phase":"PHASE1","title":"Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-10","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT00770718","phase":"PHASE1","title":"Factor VII, Prothrombin Complex Concentrate, and Fresh Frozen Plasma in Warfarin-Related Intracranial Hemorrhage","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-04","conditions":"Intracranial Hemorrhage","enrollment":2},{"nctId":"NCT00364182","phase":"PHASE3","title":"Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-05","conditions":"Hemophilia B","enrollment":50},{"nctId":"NCT00866606","phase":"PHASE3","title":"Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-02","conditions":"Hemophilia B","enrollment":35},{"nctId":"NCT00167973","phase":"","title":"Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-01","conditions":"Hemophilia B","enrollment":218},{"nctId":"NCT00093171","phase":"PHASE3","title":"Study Evaluating rFIX; BeneFIX® in Hemophilia B","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT00581126","phase":"PHASE4","title":"Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2001-12","conditions":"Hemophilia B","enrollment":14},{"nctId":"NCT00037557","phase":"PHASE3","title":"Study Evaluating rFIX; BeneFIX in Severe Hemophilia B","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-09","conditions":"Hemophilia B","enrollment":20},{"nctId":"NCT00093210","phase":"PHASE3","title":"Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"","conditions":"Hemophilia B","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":264,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BAX326","RIXUBIS"],"phase":"marketed","status":"active","brandName":"Recombinant factor IX","genericName":"Recombinant factor IX","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"Recombinant factor IX replaces the missing or deficient clotting factor IX to restore the intrinsic coagulation pathway and enable normal blood clot formation. Used for Hemophilia B (factor IX deficiency) — prevention and treatment of bleeding episodes, Hemophilia B — perioperative management and surgical prophylaxis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}